JP2018538308A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538308A5
JP2018538308A5 JP2018532038A JP2018532038A JP2018538308A5 JP 2018538308 A5 JP2018538308 A5 JP 2018538308A5 JP 2018532038 A JP2018532038 A JP 2018532038A JP 2018532038 A JP2018532038 A JP 2018532038A JP 2018538308 A5 JP2018538308 A5 JP 2018538308A5
Authority
JP
Japan
Prior art keywords
composition
antibody
use according
bladder
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018532038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538308A (ja
Filing date
Publication date
Priority claimed from GBGB1522311.8A external-priority patent/GB201522311D0/en
Application filed filed Critical
Publication of JP2018538308A publication Critical patent/JP2018538308A/ja
Publication of JP2018538308A5 publication Critical patent/JP2018538308A5/ja
Pending legal-status Critical Current

Links

JP2018532038A 2015-12-17 2016-12-19 膀胱癌のための膀胱内療法 Pending JP2018538308A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522311.8A GB201522311D0 (en) 2015-12-17 2015-12-17 Use
GB1522311.8 2015-12-17
PCT/EP2016/081798 WO2017103280A1 (en) 2015-12-17 2016-12-19 Intravesical therapy for bladder cancer

Publications (2)

Publication Number Publication Date
JP2018538308A JP2018538308A (ja) 2018-12-27
JP2018538308A5 true JP2018538308A5 (enExample) 2020-02-06

Family

ID=55311161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532038A Pending JP2018538308A (ja) 2015-12-17 2016-12-19 膀胱癌のための膀胱内療法

Country Status (12)

Country Link
US (2) US20180371101A1 (enExample)
EP (1) EP3390448B1 (enExample)
JP (1) JP2018538308A (enExample)
KR (1) KR102878726B1 (enExample)
CN (1) CN108699147B (enExample)
AU (1) AU2016372570B2 (enExample)
DK (1) DK3390448T3 (enExample)
ES (1) ES2981986T3 (enExample)
FI (1) FI3390448T3 (enExample)
GB (1) GB201522311D0 (enExample)
PL (1) PL3390448T3 (enExample)
WO (1) WO2017103280A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN118634323A (zh) 2016-12-07 2024-09-13 艾吉纳斯公司 抗体和其使用方法
MX2020005692A (es) * 2017-12-01 2020-09-25 Sbi Pharmaceuticals Co Ltd Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.
EP4676462A1 (en) 2023-03-07 2026-01-14 Photocure ASA Therapy for bladder cancer
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ303251A (en) 1995-03-10 2000-10-27 Photocure Asa Use of esters of 5-aminolevulinic acid as photosensitising agents in photochemotherapy
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 pd-1에 대한 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
PL2342226T3 (pl) * 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
JP6312659B2 (ja) 2012-05-31 2018-04-18 ジェネンテック, インコーポレイテッド Pd−1系結合アンタゴニスト及びvegfアンタゴニストを用いた癌の治療方法
CN108135934B (zh) * 2015-10-19 2024-09-10 永恒生物科技股份有限公司 通过组合疗法治疗实体或淋巴肿瘤的方法
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use

Similar Documents

Publication Publication Date Title
RU2013121788A (ru) Ингибиторы репликации вич
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
EA201792541A3 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
FI3390448T3 (fi) Intravesikaalinen hoito virtsarakon syöpää varten
CR20190247A (es) Métodos para el tratamiento de la atrofia muscular y enfermedad ósea con el uso de proteínas trap híbridas novedosas del ligando actriib
EA201390840A1 (ru) Полициклический lpaантагонист и его применение
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
FI3484446T3 (fi) Vasta-ainekoostumuksia
IL311873A (en) Combination therapy for treating malignancies
ATE553772T1 (de) Verwendung von lvv-hämorphin-6 und optional af12198 als therapeutische(s) mittel
EA201592287A1 (ru) Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения
AU2020256847B2 (en) Method of treating tumours
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
JP2018537514A5 (enExample)
JP2020502198A5 (enExample)
FI3463436T3 (fi) Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää
RU2014145841A (ru) Терапевтический биопрепарат для лечения гепатоцеллюлярной карциномы
KR102787188B1 (ko) 방광암에 대한 신보조 요법
JP2012522841A5 (enExample)
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
JP2019501161A5 (enExample)
RU2018123834A (ru) Способ фотодинамической терапии (фдт) для рака мочевого пузыря
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента